Get the Stockscreener App
0.6105
4.04%
0.0237
Vistagen Therapeutics Inc stock is traded at $0.6105, with a volume of 1.17M.
It is up +4.04% in the last 24 hours and up +10.96% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$0.5868
Open:
$0.5974
24h Volume:
1.17M
Relative Volume:
1.55
Market Cap:
$24.19M
Revenue:
$1.04M
Net Income/Loss:
$-67.50M
P/E Ratio:
-0.3176
EPS:
-1.9222
Net Cash Flow:
$-60.67M
1W Performance:
-2.44%
1M Performance:
+10.96%
6M Performance:
-84.70%
1Y Performance:
-72.87%
1-Day Range:
$0.5963
$0.64
1-Week Range:
$0.58
$0.666
52-Week Range:
$0.43
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.6105 | 24.19M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Downgrade | Jefferies | Buy → Hold |
| Dec-17-25 | Downgrade | Maxim Group | Buy → Hold |
| Dec-17-25 | Downgrade | Stifel | Buy → Hold |
| Dec-17-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Trial of Fasedienol Nasal Spray for Social Anxiety Disorder; Topline Results Expected Q2 2026 - Minichart
ex_558852.htm - SEC.gov
Vistagen (VTGN) completes PALISADE-4 randomized phase, eyes Q2 2026 data - Stock Titan
Vistagen (VTGN) Wraps Up Final Patient Visits in Phase 3 Anxiety Trial - GuruFocus
Vistagen completes enrollment in phase 3 anxiety trial By Investing.com - Investing.com Canada
Public-speaking challenge study ends; Vistagen data due this quarter - Stock Titan
Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect - ACCESS Newswire
2026-05-05 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect | NDAQ:VTGN | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) S - The National Law Review
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Vistagen (VTGN) wins FDA go-ahead to advance refisolone Phase 2 hot flash studies - Stock Titan
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop - Schubert Jonckheer & Kolbe
VistaGen appoints Nick Tressler as CFO - MSN
Vistagen Therapeutics Inc (MEX:VTGN) Competitors 2026 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Reach Out - ACCESS Newswire
2026-04-26 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Reach Out | NDAQ:VTGN | Press Release - Stockhouse
Who's Buying or Selling Vistagen Therapeutics Inc (MEX:VTGN) Stock Today? - GuruFocus
Vistagen Therapeutics Inc Stock Intrinsic Values | MEX:VTGN - GuruFocus
Vistagen Therapeutics Inc Stock Historical Valuations - GuruFocus
Vistagen Therapeutics Inc Stock Warning Signs - GuruFocus
Vistagen Therapeutics Inc (MEX:VTGN) Stock Price, Trades & News - GuruFocus
Q3 2026 Vistagen Therapeutics Inc Earnings Call Transcript - GuruFocus
Q3 2025 Vistagen Therapeutics Inc Earnings Call Transcript - GuruFocus
Q1 2026 Vistagen Therapeutics Inc Earnings Call Transcript - GuruFocus
Q2 2026 Vistagen Therapeutics Inc Earnings Call Transcript - GuruFocus
Vistagen Therapeutics Inc (MEX:VTGN) Stock Earnings Transcripts - GuruFocus
Vistagen Therapeutics (VTGN) price target decreased by 50.00% to 7.40 - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Ther - The National Law Review
Vistagen advances PALISADE-4 trial with $61.8M in cash while refining placebo mitigation strategies - MSN
Vistagen Therapeutics (VTGN) Stock: Buy Decision Breakdown | Q1 2026: Earnings Beat EstimatesCertified Trade Ideas - Cổng thông tin điện tử tỉnh Tây Ninh
VistaGen Therapeutics, Inc. (VTGN) reports Q3 loss, lags revenue estimates - MSN
Breakthrough for Vistagen (VTGN) as FDA Approves Phase 2 Development - GuruFocus
Hot flash nasal spray moves ahead after FDA allows U.S. study - Stock Titan
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause - ChartMill
Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors - WFXG
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm - TMX Newsfile
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update - ADVFN
Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeuti - The National Law Review
2026-04-16 | Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Shareholders to Inquire about Securities Investigation | NDAQ:VTGN | Press Release - Stockhouse
Vistagen Therapeutics Inc (MEX:VTGN) Stock Price & 30 Year Financial Data - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Connect - ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Vistagen Therapeutics, Inc. Files Form 8-K with SEC – Company Information, Address, and Stock Details (April 2026) - Minichart
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.97%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):